Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Microbiome therapeutics and patent protection

Obtaining patent protection for microbiome therapeutics has been affected profoundly by the US Supreme Court decisions in Myriad and Mayo, which redefined the scope of which natural phenomena, including microbiome therapeutics, are patent eligible.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2


  1. Young, V. B. Br. Med. J. 356, j831 (2017).

    Article  Google Scholar 

  2. Marchesi, J. R. et al. Gut 65, 330–339 (2016).

    Article  Google Scholar 

  3. Brody, J. E. Unlocking the secrets of the microbiome. The New York Times (7 November 2017).

  4. Anonymous. The human microbiome: me, myself, us. The Economist (18 August 2012).

  5. Zhang, F., Luo, W., Shi, Y., Fan, Z. & Ji, G. Am. J. Gastroenterol. 107, 1755 (2012). author reply 1755–1756.

    Article  Google Scholar 

  6. Borody, T. J. & Campbell, J. Expert Rev. Gastroenterol. Hepatol. 5, 653–655 (2011).

    Article  Google Scholar 

  7. van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).

    Article  Google Scholar 

  8. Atarashi, K. et al. Science 331, 337–341 (2011).

    Article  CAS  Google Scholar 

  9. Tanoue, T. et al. Nature 565, 600–605 (2019).

    Article  CAS  Google Scholar 

  10. Almeida, A. et al. Nature 568, 499–504 (2019).

    Article  CAS  Google Scholar 

  11. DeFilipp, Z. et al. N. Engl. J. Med. 381, 2043–2050 (2019).

    Article  Google Scholar 

  12. 35 USC § 112(a).

  13. Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 US 127 (1948).

  14. Diamond v. Chakrabarty, 447 US 303 (1980).

  15. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 US 66 (2012).

  16. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 US 576 (2013).

  17. USPTO. Interim Guidance on Patent Subject Matter Eligibility, 79 FR 74618 (16 December 2014).

  18. PTAB Case Number PGR2019-00002 (2019).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Erik J. Spek.

Ethics declarations

Competing interests

M.J.F. is a partner in the intellectual property group at Nixon Peabody LLP. E.J.S. is an employee of Vedanta Biosciences, Inc., a company developing therapies for diseases based on human microbiome-derived bacteria.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

FitzGerald, M.J., Spek, E.J. Microbiome therapeutics and patent protection. Nat Biotechnol 38, 806–810 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research